Modulation of the DNA repair pathway is an emerging target for the development of anticancer drugs. DNA interstrand cross-links (ICLs), one of the most severe forms of DNA damage caused by anticancer drugs such as cisplatin and mitomycin C (MMC), activates the Fanconi anemia (FA)/BRCA DNA repair pathway. Inhibition of the FA/BRCA pathway can enhance the cytotoxic effects of ICL-inducing antican...

The function of BRCA1 and BRCA2 in DNA repair could affect the sensitivity of cells to cytotoxic agents, and would therefore be an important component of planning therapy for breast and ovarian cancers. Previously, both BRCA1- and BRCA2-deficient tumors were shown to be sensitive to mitomycin C, and the mechanism was presumed to be a defect in the repair of interstrand crosslinks by homologous ...

Objectives: The objective of this study was to evaluate the long-term cost-effectiveness of germline BRCA1 and BRCA2 (collectively termed ‘BRCA’) testing in women with epithelial ovarian cancer, and testing for the relevant mutation in first and second degree relatives of BRCA mutation-positive individuals, compared with no testing. Female BRCA mutation-positive relatives of ovarian cancer pati...

OBJECTIVES To evaluate the long-term cost-effectiveness of germline BRCA1 and BRCA2 (collectively termed "BRCA") testing in women with epithelial ovarian cancer, and testing for the relevant mutation in first- and second-degree relatives of BRCA mutation-positive individuals, compared with no testing. Female BRCA mutation-positive relatives of patients with ovarian cancer could undergo risk-red...

PURPOSE We investigated the relationship between BRCA mutations, pathological findings, and magnetic resonance imaging (MRI) features in patients with breast cancer at risk for the mutation. METHODS Genetic testing for BRCA mutations was performed in 275 breast cancer patients with at least one risk factor for the mutation. Using the breast imaging reporting and data system MR lexicon, morpho...

BACKGROUND Germline mutations in the BRCA1 and BRCA2 genes are associated with an increased risk of breast cancer. Whether women with breast cancer who have inherited mutations in these genes have a different outcome after breast conservation therapy than women with "sporadic" cancer is unresolved. Consequently, we compared the outcomes after breast conservation therapy in Ashkenazi women with ...

Predisposition to breast and ovarian cancer has been attributed to mutant BRCA1 alleles in 90% of hereditary combined tumors and in 45% of hereditary breast cases, whereas mutations in BRCA2 gene are thought to account for about 35% of inherited breast cancers. On the other hand, the presence of mutations in the sporadic forms of these tumors is an infrequent event. This suggests that tumors ar...

Objective: This study investigated the prevalence of BRCA1/2 gene mutations and their relationship with clinical pathological parameters in Uyghur and Han sporadic breast cancer patients in the Xinjiang Uyghur Autonomous Region. Methods: Polymerase chain reaction (PCR) and DNA sequencing were used to detect mutations of the BRCA1 (exons 2, 11 (11A and 11B) and 20) and BRCA2 (exon 11) genes in p...

Background: Breast cancer is one of the most common cancers among women around world. Some occult breast can be missed when using ultrasound or mammogram alone. Considering this background, study was performed to highlight improved diagnostic efficacy identifying both and as a combined modality.Methods: A total 150 cases suspected were studied over period 2 years. Ultrasonography, mammography d...

Breast carcinoma is one of the most common tumors in women. The immune microenvironment, especially T cell infiltration, related to occurrence and prognosis breast carcinoma. This study investigated gene expression patterns associated with tumor-infiltrating CD4+ CD8+ cells invasive carcinomas. data corresponding clinical phenotype from Cancer Genome Atlas Invasive Carcinoma (TCGA-BRCA) were do...